Versant Venture Capital VII, L.P. - Jan 3, 2022 Form 4 Insider Report for CHINOOK THERAPEUTICS, INC. (KDNY)

Role: 10%+ Owner
Signature: /s/ Robin L. Praeger, Managing Director of Versant Ventures VII GP-GP, LLC, general partner of Versant Ventures VII GP, L.P., general partner of Versant Venture Capital VII, L.P.
Stock symbol: KDNY
Transactions as of: Jan 3, 2022
Transactions value $: -$16,000,200
Form type: 4
Date filed: 1/5/2022, 04:16 PM
Previous filing: Aug 31, 2021
Next filing: Apr 6, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KDNY	Common Stock	Sale	-$9.6M	-600K	-14.21%	$16.00	3.62M	Jan 3, 2022	Direct	F1, F2, F3
transaction	KDNY	Common Stock	Sale	-$4.93M	-308K	-14.19%	$16.00	1.86M	Jan 3, 2022	See Footnote	F1, F2, F4
transaction	KDNY	Common Stock	Sale	-$1.47M	-92K	-14.28%	$16.00	552K	Jan 3, 2022	See Footnote	F1, F2, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Venture Capital VII, L.P. ("Versant VII"), Versant Voyageurs I, L.P. ("Versant Voyageurs I") and Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"), respectively.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
F3	These securities are held of record by Versant VII. Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Versant VII GP-GP, Versant VII GP and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.
F4	These securities are held of record by Versant Voyageurs I. Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. Jerel C. Davis, a member of the Issuer's board of directors, is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Versant Voyageurs I GP Company and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.
F5	These securities are held of record by Versant I Parallel. Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP, Versant Voyageurs I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.